Trader’s Buzzers: Advanced Disposal Services South, LLC (ADSW), Zynga, Inc. (ZNGA), Merck & Co., Inc. (MRK)

Advanced Disposal Services South, LLC (ADSW) has seen decrease in value by 0% so far this year. The stock was up close to 11.11% on active volume in last trading session and closed at $20 per share. After the recent gain, the stock is currently holding 0% below its 52 week high of $21.5 and 0% below its 12-month low of $19.51. The shares are down by over 0% in the last three months, and the RSI indicator value of 0 is bullish. They are not pointing to a rebound in the stock. We should get in as it looks to have found a bottom.

Zynga, Inc. (ZNGA) failed to extend gains with the stock declining -1.68% or $-0.05 to close the day at $2.92 on light trading volume of 11.59M shares, compared to its three month average trading volume of 13.58M. The San Francisco California 94103 based company has been outperforming the multimedia & graphics software group over the past 52 weeks, with the stock gaining 21.16%, compared to the industry which has advanced 33.1% over the same period. With RSI of 56.32, the stock should still continue to rise and get closer to its one year target estimate of $3.17, making it a hold for now.

Zynga Inc. develops, markets, and operates social games as live services played on the Internet, social networking sites, and mobile platforms in the United States, North America, Asia, and the European Union. It offers its online social games primarily under the Slots, Words With Friends, Zynga Poker, and FarmVille franchises. The company’s games are accessible on mobile platforms, Facebook, and other social networks, as well as Zynga.com. It also provides advertising services to advertising agencies and brokers. The company was formerly known as Zynga Game Network Inc. and changed its name to Zynga Inc. in November 2010. Zynga Inc. was founded in 2007 and is headquartered in San Francisco, California.

Merck & Co., Inc. (MRK) dropped $-0.14 to close the day at a new closing price of $62.66, a -0.22% decrease in value from its previous closing price that moved the stock 33.82% above its 52 week low of $47.97. A total of 11.43M shares exchanged hands during the day compared with its three month average trading volume of 9.66M. The stock, which fluctuated between $61.74 and $62.69 during the day, currently situated -1.38% below its 52 week high. The stock is up by 0.4% in the past one month and up by 6.35% over the past three months. With a one year target estimate of $66.11 and RSI of 52.16, the stock still has upside potential, making it a hold for now.

Merck & Co., Inc. provides health care solutions worldwide. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also provides neuromuscular blocking agents for use in surgery; anti-bacterial products for skin and skin structure infections; cholesterol modifying medicines; non-sedating antihistamine; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors; treat melanoma and metastatic non-small-cell lung cancer; and prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it provides antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics for the treatment of C. difficile, and vaccines against bacterial and viral disease in fish. Additionally, the company offers companion animal products, such as ointments for acute and chronic otitis; diabetes mellitus treatment for dogs and cats; anthelmintic products; chewable tablets to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.